Chaoying Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chaoying Ding has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Marianthi Ierapetritou
University of Delaware
2 shared publications André C. Dumetz
Biopharm Drug Substance Development, GSK, King of Prussia, PA 19406, US
1 shared publicationBo Liu
1 shared publication- Christopher Gerberich
Biopharm Drug Substance Process Development, GSK, King of Prussia, PA 19406, USA
1 shared publication Christopher Gillespie
External Manufacturing Operations Merck & Co., Inc. Kenilworth New Jersey USA
1 shared publicationDayong Lu
Department of Materials Science and Engineering, Jilin Institute of Chemical Technology, Jilin 132022, PR China
1 shared publication
Latest Publications
- 15 December 2024
- Published by Elsevier in Journal of Chromatography A
- Vol. 1741, 465601
Probabilistic pressure-flow operating space for chromatographic resins using mechanistic modeling
- 15 December 2024
- Published by Elsevier in Journal of Chromatography A
- Vol. 1741, 465601
Probabilistic pressure-flow operating space for chromatographic resins using mechanistic modeling
- 1 January 2023
- Published by Springer Nature
- p. 179-211
Towards Digital Twin for Biopharmaceutical Processes: Concept and Progress
- 1 January 2023
- Published by Springer Nature
- p. 179-211
Towards Digital Twin for Biopharmaceutical Processes: Concept and Progress
- 26 September 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (12) , 3567-3583
Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment
Continuous biomanufacturing is a promising alternative to current batch operation as it offers benefits in terms of improved productivity, product quality, and reduced footprint. This study aims to build a fully integrated continuous platform for monoclonal antibody (mAb) production incorporating novel technologies (like intensified seed expansion and continuous high cell density perfusion operations, single‐pass tangential flow filtration, and single‐use technologies) as well as media and buffer preparation steps. Economic assessment is performed on the basis of the total cost of goods (COGs), which is $102.2/g in the base‐case scenario with a bioreactor scale of 500 L. E‐factor is used as an environmental indicator and the result shows that 4865.6kg of process water and 11.1 kg of consumables are required to produce 1 kg mAbs. After the development and analysis of the benchmark process, scenario analysis is performed to assess the impacts of the bioreactor scale (60–2000 L) and upstream titers (1.12–2.08 g/L) on the process economics as well as on the environmental footprint. With the increase of bioreactor scale and mAb titer, the operating COGs per unit product decrease. Moreover, increasing the mAb titer is more favorable in terms of the ecological impacts. To investigate the production capacity, the upstream production is increased and the downstream bottlenecks are determined. It is found that only the multicolumn chromatographic (MCC) operations become the process bottleneck and the order of the MCC unit operation that becomes the process bottleneck depends on capacity utilization for that step. Finally, a new platform is built with the integration of membrane chromatography and the two designed processes are compared in terms of economic and ecological impacts.
- 26 September 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (12) , 3567-3583
Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment
Continuous biomanufacturing is a promising alternative to current batch operation as it offers benefits in terms of improved productivity, product quality, and reduced footprint. This study aims to build a fully integrated continuous platform for monoclonal antibody (mAb) production incorporating novel technologies (like intensified seed expansion and continuous high cell density perfusion operations, single‐pass tangential flow filtration, and single‐use technologies) as well as media and buffer preparation steps. Economic assessment is performed on the basis of the total cost of goods (COGs), which is $102.2/g in the base‐case scenario with a bioreactor scale of 500 L. E‐factor is used as an environmental indicator and the result shows that 4865.6kg of process water and 11.1 kg of consumables are required to produce 1 kg mAbs. After the development and analysis of the benchmark process, scenario analysis is performed to assess the impacts of the bioreactor scale (60–2000 L) and upstream titers (1.12–2.08 g/L) on the process economics as well as on the environmental footprint. With the increase of bioreactor scale and mAb titer, the operating COGs per unit product decrease. Moreover, increasing the mAb titer is more favorable in terms of the ecological impacts. To investigate the production capacity, the upstream production is increased and the downstream bottlenecks are determined. It is found that only the multicolumn chromatographic (MCC) operations become the process bottleneck and the order of the MCC unit operation that becomes the process bottleneck depends on capacity utilization for that step. Finally, a new platform is built with the integration of membrane chromatography and the two designed processes are compared in terms of economic and ecological impacts.
- 1 June 2015
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 633, 300-305
Facile in situ solvothermal method to synthesize MWCNT/SnIn4S8 composites with enhanced visible light photocatalytic activity
- 1 June 2015
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 633, 300-305
Facile in situ solvothermal method to synthesize MWCNT/SnIn4S8 composites with enhanced visible light photocatalytic activity